News Column

Researchers at Methodist Hospital Research Institute Report Findings in Melanomas (Serum peptidomic biomarkers for pulmonary metastatic melanoma...

August 15, 2014



Researchers at Methodist Hospital Research Institute Report Findings in Melanomas (Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay)

By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Melanomas have been published. According to news reporting originating in Houston, Texas, by NewsRx journalists, research stated, "The significant mortality rate associated with metastatic melanoma, which exceeds the number of deaths attributed to the primary tumor, is primarily due to poor diagnosis and increased resistance to systemic therapy. Early detection and treatment of invasive melanoma are therefore crucial to increase survival rates."

The news reporters obtained a quote from the research from Methodist Hospital Research Institute, "Low molecular weight proteins and peptides have garnered significant interest as biomarker candidates as they potentially represent a snap shot of pathological condition within the body and, by extension, the organism as a whole. We have developed a nanoporous silica-based platform to segregate the low molecular weight from the high molecular weight protein fraction to aid in the detection of peptides from serum samples using mass spectrometry. The combination of sample treatment with our platform, MALDI-TOF MS and following biostatistical analysis led to the discovery and identification of 27 peptides that are potential biomarkers associated with the development of pulmonary metastatic melanoma."

According to the news reporters, the research concluded: "We strongly believe our findings can assist to discover stage-specific peptide signatures and lead to more specific and personalized treatments for patients suffering from pulmonary metastatic melanoma."

For more information on this research see: Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. Cancer Letters, 2013;334(2):202-10. (Elsevier - www.elsevier.com; Cancer Letters - www.elsevier.com/wps/product/cws_home/506050)

Our news correspondents report that additional information may be obtained by contacting J. Fan, Dept. of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, United States. Additional authors for this research include Y. Huang, I. Finoulst, H.J. Wu, Z. Deng, R. Xu, X. Xia, M. Ferrari, H. Shen and Y. Hu (see also Melanomas).

Keywords for this news article include: Texas, Houston, Melanomas, United States, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters